| Send2Press.com • Today is Monday, February 13, 2012 | A Member of the Neotrope News Network |  |
 Search Send2Press.com: |
|
|
|
Biotechnology Industry News from Send2Press Newswire
News Index for Monday, February 13, 2012 Reaction Biology Launches Recombinant Methyltransferase Line Mon, 24 Oct 2011, 14:25:48 EST — Edited by Debra Tone MALVERN, Pa., Oct. 24, 2011 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation ('RBC'), a leading contract research organization providing drug discovery services in epigenetics, today announced the rollout of a new product line, recombinant proteins for epigenetic research. RBC's initial offerings will emphasize the histone methyltransferases (HMTs), including exclusive targets for which there has been no previous commercial source. Americans Travel to Mexico for Stem Cell Stimulation Therapies and E+ Peptide Cancer Vaccine - Treatments Not Yet Offered in U.S. Tue, 09 Aug 2011, 08:58:11 EST — Edited by Debra Tone KIRKLAND, Wash. (SEND2PRESS NEWSWIRE) -- Many Americans - unsatisfied with traditional treatments for cancer, diabetes, osteoporosis, and other intractable diseases - are looking south for advanced remedies. 'We're struggling to keep up with demand,' says Dr. Oscar E. Castro, head of Regenerative Cellular Therapy (RCT), of Puerto Penasco, Sonora, Mexico. To Reach, Perchance to Kill the Cancer: A Soliloquy from Epeius Nanotechnologies Opposes that 'Sea of Troubles' Tue, 07 Sep 2010, 20:46:15 EST — Edited by Carly Zander SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, reports the publication of a landmark paper in clinical oncology. Following up on its advanced U.S. Phase I/II clinical trials of Rexin-G in chemo-resistant metastatic pancreatic cancer (Molecular Therapy, 2010, 18: 435-441), which gained both Orphan Drug and FDA Fast Track Status, this new paper documents the molecular mechanisms-of-action of Rexin-G. 12 EDGE Fund Applications Approved to Advance to Second Phase of 2010 Funding Process Tue, 20 Jul 2010, 14:13:25 EST — Edited by Debra Tone OKLAHOMA CITY, Okla. (SEND2PRESS NEWSWIRE) -- The Economic Development Generating Excellence Policy Board announced that 12 pre-proposal applications from an initial field of 62 have been approved to advance to the next step in the 2010 funding evaluation process. This year represents the third round of funding disbursement from the EDGE fund; in 2009, five awards were granted totaling $7.5 million. This year, around $6.5 million will be available for award distribution. Lower Back Pain is Targeted by LifeModeler, Inc. with Newly Released Software Tue, 23 Jun 2009, 08:59:31 EST — Edited by Carly Zander SAN CLEMENTE, Calif. (SEND2PRESS NEWSWIRE) -- LifeModeler, Inc., the leading global provider of biomechanical human body simulation tools and services, has released LumbarSIM™, a new product that adds to its family of unique 'virtual prototyping' software. This latest innovation directly addresses the needs of orthopedic device manufacturers and surgeons seeking ways to respond to the growing numbers of patients experiencing lower back pain. FDA Grants Epeius Biotechnologies' Rexin-G A Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas Tue, 08 Jul 2008, 18:01:25 EST — Edited by Debra Tone SAN MARINO, Calif., July 8 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of all soft tissue sarcomas. This latest approval is the third clinical indication for which Rexin-G has been formally recognized by the FDA in the United States. Epeius Biotechnologies Leads with Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma RandD Summit Conference in Boston Thu, 18 Oct 2007, 22:13:00 EST — Edited by Carly Zander SAN MARINO, Calif. and BOSTON, Mass. - Oct. 18 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies Inc., has accepted an invitation to give the lead keynote address on 'The Advent of Pathotropic Medicine for Cancer' at the Global Pharma R&D Summit 2007 to be held in Boston. California Biotechnology Company Takes Aim at Pancreatic Cancer With an Advanced Phase I/II Clinical Trial Using Rexin-G(TM), a Targeted Injectable Gene Delivery System Tue, 10 Jul 2007, 14:00:00 EST — Edited by Chris Simmons SAN MARINO, Calif. - July 10 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that an advanced Phase I/II clinical trial using intravenous Rexin-G(TM) for pancreatic cancer that is refractory to standard chemotherapy will open in the summer of 2007 in Los Angeles, California. Rexin-G is the world's first tumor-targeted injectable gene delivery system that is designed to seek out and destroy both primary tumors and metastatic cancers. Osmetech Licenses Self-Assembling Monolayer (SAM) Technology to Minerva Biotechnologies Corporation Mon, 18 Jun 2007, 23:36:00 EST — Edited by Chris Simmons PASADENA, Calif. - June 18 (SEND2PRESS NEWSWIRE) -- Osmetech plc (LSE, AIM; OMH) today announced that it has granted a non-exclusive research license to Waltham, Massachusetts, US-based Minerva Biotechnologies Corporation ('Minerva') for use of Osmetech's self-assembling monolayer (SAM) technology in conjunction with Minerva's proprietary nanoparticle technology. Mark Whitacre, Ph.D. Joins Management Team at Cypress Systems, Inc. Wed, 13 Jun 2007, 14:15:00 EST — Edited by Chris Simmons FRESNO, Calif. - June 13 (SEND2PRESS NEWSWIRE) -- Cypress Systems, Inc, a Fresno CA based biotechnology company, announced that it has hired Mark Whitacre, Ph.D. Dr. Whitacre joined the executive management team effective January 1, 2007 as COO & President, Technology and Business Development, following the opening of a new office in Pensacola, Florida in December, 2006. Epeius Biotechnologies to Present the Advent of Tumor Targeting Technology and the Clinical Development of its Lead Anti-Cancer Agent, Rexin-G(TM), at Upcoming Bioventure, Nanotechnology and Nanomedicine Conferences Tue, 15 May 2007, 14:00:00 EST — Edited by Chris Simmons SAN MARINO, Calif. - May 15 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies, has accepted an invitation to speak during the 9th annual C21 BioVentures Conference. On May 23 at 11:15 am, Dr. Hall will present the scientific principles, clinical validation, and global development status of the company's innovative tumor-targeting technology embodied in its lead product, Rexin-G. Rexin-G(TM), The World's First Tumor-Targeted Gene Therapy Vector, Stymies Metastatic Cancer Mon, 06 Nov 2006, 13:36:00 EST — Edited by Christopher Simmons SAN MARINO, Calif. and MANILA, Philippines - Nov. 6 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies today announced the publication of clinical data from studies conducted at the University of the Philippines, Asian Hospital and Medical Center, Makati Medical Center, Manila, Philippines and Lutheran Medical Center, New York, USA, revealing the safety and single agent efficacy of Rexin-G(TM) for the treatment of a broad spectrum of chemotherapy-resistant cancers. Epeius Biotechnologies Affirms Leadership Role in The Development of Genetic Medicine Wed, 11 Oct 2006, 16:18:00 EST — Edited by Christopher Simmons SAN MARINO, Calif. - Oct. 11 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced that Dr. Frederick Hall, President and CEO of Epeius Biotechnologies, has accepted an invitation to speak at the upcoming Global Pharmaceutical Research & Development Summit held on Oct. 24 at 4:10 p.m. (PT) in Anaheim, Calif. Dr. Hall will present the current status of global development and the broad pharmaceutical indications for the company's innovative targeting technology platform that has enabled Epeius to develop Rexin-G(TM). Reaction Biology Corp. Awarded NIH SBIR Grant for Kinase Radioisotope Microarray Screening Development Tue, 20 Jun 2006, 15:15:00 EST — Edited by Carly Zander MALVERN, Pa. (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation (RBC) today announced that it has been awarded an SBIR grant from the National Cancer Institute to create a new kinase profiling and high throughput screening method using radioisotopes and microarrays. The $940,000 grant will be used to migrate the current well-plate radioisotope methods onto RBC's DiscoveryDot nanoliter screening platform. Key Organics Ltd and Reaction Biology Corporation Announce New Library Screening Format Thu, 01 Jun 2006, 05:12:00 EST — Edited by Christopher L. Simmons CORNWALL, UK and MALVERN, PA - June 1 (SEND2PRESS NEWSWIRE) -- Key Organics Ltd and Reaction Biology Corporation today announced that they have teamed up to provide a new library screening format to customers. Beginning this summer, the entire Key Bionet library of 37,500 diverse drug-like compounds will be offered for 'rental' screening on RBC's DiscoveryDot(TM) platform. For the first time, customers will be able to screen the Key library without having to purchase it outright. Epeius Biotechnologies Establishes Corporate Headquarters in San Marino, California - Facilities Include a Clinical Research Unit Dedicated to Evaluating New Genetic Medicine for Cancer Tue, 04 Apr 2006, 18:08:00 EST — Edited by Debra Tone SAN MARINO, CA - Apr. 4 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today the establishment of its main corporate headquarters in San Marino, California. The specialty pharmaceutical company has been granted Orphan Drug Status by the FDA for its lead product Rexin-G(TM), an innovative anti-cancer agent that seeks out and destroys metastatic disease. Rexin-G(TM) has been tested in a wide variety of cancer types, including pancreatic cancer, breast cancer, colon cancer, uterine cancer, laryngeal cancer, smooth muscle cancer (leiomyosarcoma) and skin cancer (malignant melanoma). Reaction Biology Corp. Awarded Phase II SBIR Grant for Drug Discovery Tue, 09 Aug 2005, 10:56:00 EST — Edited by Christopher Simmons MALVERN, PA - August 9 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation ('RBC') today announced that it has been awarded a Phase II SBIR grant from the National Institutes of Health to apply its new DiscoveryDot(TM) High Throughput Screening technology for drug discovery. Clinical Trial For Pancreatic Cancer Opens at Mayo Clinic Using Tumor-Targeted Gene Therapy Vector Fri, 15 Jul 2005, 12:03:00 EST — Edited by Christopher Simmons LOS ANGELES, Calif. - July 15 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, announced today that a Phase I clinical trial has opened at Mayo Clinic Cancer Center, Rochester, Minnesota to test the safety of Rexin-G(TM), the first tumor-targeted gene therapy vector to gain Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. The clinical protocol has passed the rigorous reviews of the FDA, the NIH/Recombinant Advisory Committee, and the Institutional Review Board of Mayo Clinic. Reaction Biology Corporation Awarded NIH Kinase Grant Tue, 21 Jun 2005, 10:21:00 EST — Edited by Christopher Simmons MALVERN, PA - June 21 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation ('RBC') today announced that it has been awarded a Phase I SBIR grant from the National Institutes of Health to develop its new microarray kinase screening technology for testing compounds in nanoliter reactions. Phase I Clinical Trial for Advanced Colon and Pancreatic Cancer Opens in New York Using Rexin-G, the World's First Tumor-Targeted Gene Delivery Vector Tue, 05 Apr 2005, 12:52:00 EST — Edited by Christopher Simmons LOS ANGELES, Calif. -- (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation (www.epeiusbiotech.com) announced today that a Phase I clinical trial has opened in New York to test the safety and efficacy of Rexin-G, the leading tumor-targeted gene delivery system (vector) developed for the treatment of metastatic colon and pancreatic cancer. In 2003, Rexin-G gained FDA approval as an Orphan Drug based on clinical demonstrations of the medical utility of Rexin-G as an effective treatment for pancreatic cancer.
<< prev
next >>
|
Follow Send2Press on Social Sites: 
Latest Send2Press Newswire Stories:
|
View our news channels by industry topics, by U.S. States, or by selected U.S. Cities:
Site Design and Content is Copr. © 1983 - 2011 Neotrope® - All rights reserved. Send2Press® is a reg. trademark and service mark of NEOTROPE.
Press Release Writing | About Send2Press | Meet Our Staff | Contact Us | Our Services | Help Desk | Legal | Privacy | How-To Articles | RSS Feeds | Journalist Tools | Client eMediaKits | Headline Feeds | Podcast | PR News Channels | Daily News Desk | Success Stories | PRTRax™ Reader Tracking | Targeted News Distribution | Internet Marketing Services | Order PR Services | Terms of Service (TOS)
Press Release Writing | About Send2Press | Meet Our Staff | Contact Us | Our Services | Help Desk | Legal | Privacy | How-To Articles | RSS Feeds | Journalist Tools | Client eMediaKits | Headline Feeds | Podcast | PR News Channels | Daily News Desk | Success Stories | PRTRax™ Reader Tracking | Targeted News Distribution | Internet Marketing Services | Order PR Services | Terms of Service (TOS)